Teva Settles $450M DOJ Allegations Involving Copaxone Kickbacks and Price-Fixing

Teva Pharmaceuticals has reached a $450 million settlement with the U.S. Department of Justice to address allegations of breaching the Anti-Kickback Statute and the False Claims Act[1][2]. This settlement resolves claims that Teva engaged in a kickback scheme involving their multiple sclerosis medication, Copaxone, leveraging assistance foundations to cover Medicare copays and collaborating with a specialty pharmacy to facilitate price hikes from $17,000 to $73,000 annually between 2007 and 2016[2]. Additionally, the settlement includes $25 million to settle accusations of price-fixing with other generic drugmakers, impacting medications such as pravastatin, clotrimazole, and tobramycin[1]. Despite reaching this agreement, Teva has made no admission of liability and will distribute the settlement payment over six years[1].